Corcept Therapeutics announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes; patients with hypercortisolism may enter a randomized, placebo-controlled study of Korlym.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Is CORT a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept announces results from open-label portion of Phase 3 GRACE trial
- Corcept Therapeutics completes enrollment in Phase 2 DAZALS trial
